Jeffrey Kasher

Jeffrey Kasher has a diverse work experience in the pharmaceutical industry. Jeffrey has held various roles at Eli Lilly and Company, including VP of Clinical Innovation and Implementation, VP and COO of the Global Clinical Development Organization, Executive Director of the Autoimmune Platform Team, Executive Director of Discovery Biology, Managing Director of the Lilly Development Center, Director of Pharma Products, COO of the Zyprexa Development Team, and Senior Pharmacologist/Research Scientist in Drug Metabolism. During their time at Eli Lilly, Kasher was involved in significant initiatives such as establishing innovative clinical development approaches, transforming the Global Lilly Medical organization, and developing disease-state focused drug hunting teams. Additionally, Kasher has served as an Independent Director for Pro-ficiency, Catalyst Clinical Research, LLC, and Javara. In 2015, they became the President of Patients Can't Wait, LLC.

Jeffrey Kasher completed their Bachelor of Science in Chemistry from Franklin & Marshall College between 1974 and 1978. Following this, they pursued a Doctor of Philosophy (Ph.D.) in Pharmacology at State University of New York Upstate Medical University from 1978 to 1982. Jeffrey then went on to join Yale University School of Medicine as a Post Doctoral Fellow, where they studied for four years from 1982 to 1986.